2nd Quarter - Report

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER for THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Firm
Client
Income
—
Expenses
$80,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

All legislation related to Medicare site of service payment policy changes; Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals, including satellite regulations; Medicare Advantage preauthorization; Medicare Advantage access issues; Cuts to services related to cancer diagnosis and treatment; Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products; Policies related to the value of cancer care and initiatives that bend the cost curve; Issue related to site neutral payment reforms; Issues related to the FAIR Act and the work of the joint Taskforce developing a new method of cost reimbursement and federal grants

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

Issues related to the President's federal budget request; Funding levels for federal appropriation bills including Labor-HHS-Education, Homeland Security, Department of Defense, Commerce-Justice-Science that are related to biomedical research funding, healthcare delivery, training and education, protection of intellectual property and research. Funding for NIH and NCI.

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Government Issues GOV

Issues related to the reorganization of HHS and its underlying agencies: NIH, CDC, CMS, and FDA; Issues relating to clinical trials at FDA and the ability for patients to be able to access trials earlier in their treatment journey;

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Medical/Disease Research/Clinical Labs MED

Issues related to clinical trial design and patients obtaining drugs sooner in the course of the trial

LobbyistCovered position, as disclosed
EDWARD MILLER —

Contacted: Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.